---
title: Anatomical Resection in Colorectal Liver Metastases Patients
nct_id: NCT05673564
overall_status: COMPLETED
sponsor: Fudan University
study_type: OBSERVATIONAL
primary_condition: The Characteristics of CRLM Patients Who Would Benefit More From Anatomical Resection
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05673564.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05673564"
ct_last_update_post_date: 2023-01-06
last_seen_at: "2026-05-12T07:23:23.185Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Anatomical Resection in Colorectal Liver Metastases Patients

**NCT ID:** [NCT05673564](https://clinicaltrials.gov/study/NCT05673564)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 729
- **Lead Sponsor:** Fudan University
- **Conditions:** The Characteristics of CRLM Patients Who Would Benefit More From Anatomical Resection
- **Start Date:** 2012-06-01
- **Completion Date:** 2019-05-01
- **CT.gov Last Update:** 2023-01-06

## Brief Summary

The type of liver resection (anatomical resection, AR or nonanatomical resection, NAR) for colorectal liver metastases (CRLM) is subject to debate. The debate may persist because some certain prognostic factors, associated with aggressive biological behavior of tumor, have been overlooked. The aim of our study was to investigate the characteristics of patients who would benefit more from anatomical resection for colorectal liver metastases.

## Detailed Description

729 patients who underwent hepatic resection of CRLM were retrospectively collected from June 2012and May 2019. Treatment effects between AR and NAR were compared in full subgroup analyses. Tumor relapse-free survival (RFS) was evaluated by a stratified log-rank test and summarized with the use of Kaplan-Meier and Cox proportional hazards methods.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 79 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

(1)Age 18-79 years;(2) Histologically proven colorectal adenocarcinoma;

Exclusion Criteria:

(1) the histologic type of tumor was not called adenocarcinoma; (2) peritoneal metastasis; (3) number of liver metastasis \>3; (4) simultaneous anatomical and nonanatomical resections; (5) R2 resection; (6) history of previous hepatectomy; (7) incomplete data. The rest of patients were divided into 2 groups: patients undergoing an AR, and patients undergoing a NAR.
```

## Arms

- **anatomical resection group** — Anatomical resection was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these.
- **nonanatomical resection group** — Nonanatomical resection known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.

## Interventions

- **Anatomical Resection** (PROCEDURE) — Based upon the segmental anatomy of the liver according to Couinaud system, AR was defined as resection of 1 or more complete hepatic segments in our study, including bisegmentectomy, right hemihepatectomy, left hemihepatectomy, extended right hemihepatectomy, extended left hemihepatectomy, single segmentectomy, caudate lobectomy, or a combination of these. NAR, known as wedge resection, was defined as resection of the tumor with a margin of normal parenchyma without regard to hepatic anatomy.

## Primary Outcomes

- **RFS** _(time frame: 2012.6.1-2022.6.1)_ — Relapse-free survival since patients undergoing hepatic resection

## Secondary Outcomes

- **OS** _(time frame: 2012.6.1-2022.6.1)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05673564.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05673564*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*